Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Summit Therapeutics reports quarterly revenue growth as it makes progress with clinical trials

Summit, Santhera and Catabasis are all expected to give updates on their respective development programmes
young boy walking
DMD is a muscle wasting disease that primarily affects young boys

Summit Therapeutics PLC (LON:SUMM; NASDAQ:SMMT) reported a jump in third quarter revenue and continued to see progress in clinical trials for its therapies for Duchenne muscular dystrophy (DMD) and Clostridium difficile infection (CDI).

In the three months ended 31 October, revenue rose to £1.7mln from £0.6mln the same period a year earlier, boosted by Summit’s exclusive licence and collaboration agreement with Sarepta Therapeutics.

The agreement grants Sarepta rights to Summit’s utrophin modulator pipeline, including its lead clinical candidate, ezutromid, for the treatment of DMD.

Summit recognised £1.7mln of the upfront payment of £32.8mln made by Sarepta in October last year.

The total comprehensive loss for the third quarter was £1.8mln as Summit continue to invest in advancing its therapies.

Phase 2 trial of ezutromid on track

Summit chief executive Glyn Edwards said the group remains on track to report 24-week data from its Phase 2 clinical trial of ezutromid for the treatment of DMD –  a severe type of muscular dystrophy-  in the first quarter of 2018.

DMD is one of the most common, fatal genetic disorders diagnosed in children around the world. It predominantly affects boys and it results in the progressive wasting of muscles throughout the body.

“Ezutromid is a potentially disease-modifying treatment for all patients with DMD and we look forward to reporting these initial data from this proof of concept trial,” Edwards said.

Positive results from ridinilazole trial

During the third quarter, the company also achieved another positive Phase 2 clinical trial result for ridinilazole, an antibiotic for the treatment of CDI - a bacterium that can infect the bowel and cause diarrhoea.

The company was awarded a contract worth up to US$62mln from the Biomedical Advanced Research and Development Authority (BARDA) in early September, which will help fund the Phase 3 clinical trial and regulatory development of ridinilazole.

“We are looking forward to initiating the Phase 3 clinical programme for ridinilazole in the first half of 2018 as we seek to bring this urgently needed treatment to patients,” said Edwards.

"The ongoing support of our shareholders is allowing us to continue to advance these two therapies that have the potential to enhance the quality of life of patients and families living with the burden of DMD and CDI."

Summit hosts DMD awareness day

The third quarter results were released alongside the group's announcement that it was teaming up with several other biopharmaceutical companies and charities to host a Duchenne Muscular Dystrophy awareness day in London today (Wednesday).

The half-day event was to feature presentations and speeches by key opinion leaders, industry professionals and patients.

The sponsoring companies - which include Santhera Pharmaceuticals and Catabasis Pharmaceuticals (NASDAQ:CATB) as well as Summit - were to update on their respective development programmes for new therapeutics options and the future outlook for patients.

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Newswire
October 04 2017

Related Articles

Woman with tissue facing pollen
October 20 2017
Allergy, which saw its market share grow by a percentage point to 13%, is in a strong financial position, with £22.1mln in the bank
test tubes in a laboratory
November 06 2017
“We are delighted that RedX has exited administration as a going concern and with a strengthened board and management team that will ensure enhanced oversight and provide relevant industry expertise as well as continuity to the business”
IPF chart
Thu
Thee new terms give it the opportunity to benefit from a partnership across a whole range of fibrosis-focused treatments

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use